What is Fluence?
Fluence operates as an expertise-driven educational platform dedicated to providing professional certification and training in psychedelic therapy and integration. The company targets psychiatrists, psychotherapists, social workers, and other healthcare practitioners, equipping them with the clinical skills and knowledge necessary to deliver effective, compassionate, and evidence-based psychedelic therapy. Through dynamic, interactive online and in-person training modules, Fluence is committed to advancing the integration of psychedelic-assisted treatments into mainstream healthcare.
How much funding has Fluence raised?
Fluence has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2022): $3M with participation from Iter Investments, Baroda Ventures, The JLS Fund, Neo Kuma Ventures, Palo Santo, Evolve Ventures, Foundation Capital, and Learn Capital
Key Investors in Fluence
Iter Investments
Iter Investments is a venture capital firm dedicated to supporting emerging companies within the psychedelic ecosystem focused on behavioral and mental health. The firm aims to revolutionize mental and behavioral health by investing in innovative alternative therapeutics.
Baroda Ventures
Baroda Ventures is a top venture capital firm located in Los Angeles that invests in a variety of companies, including startups and small businesses, providing funding and support for companies in need of capital to scale their operations.
The JLS Fund
JLS Fund is a venture capital fund established in 2019 that specializes in early-stage investments in the fields of neuroscience, mental health, and related technologies, supporting companies developing psychedelic-inspired therapeutics.
What's next for Fluence?
With the recent influx of major strategic investment, Fluence is poised for significant expansion. The company's focus on professional development within the psychedelic therapy sector aligns with the growing global demand for innovative mental health solutions. Future initiatives are likely to involve scaling their training programs, potentially developing new curriculum areas, and forging strategic partnerships to broaden access to psychedelic-informed care. This capital infusion will be instrumental in solidifying Fluence's position as a leader in educating the next generation of mental health professionals equipped to utilize psychedelic modalities.
See full Fluence company page
